These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 29429376)

  • 101. Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy.
    de Angelis M; Scheipner L; Siech C; Jannello LMI; Baudo A; Bello FD; Goyal JA; Vitucci K; Tian Z; Longo N; Ahyai S; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Gandaglia G; Moschini M; Montorsi F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2024 Aug; 22(4):102119. PubMed ID: 38852435
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Immunotherapy for urothelial carcinoma: Metastatic disease and beyond.
    Poon DM
    Asia Pac J Clin Oncol; 2020 Sep; 16 Suppl 3():18-23. PubMed ID: 32852900
    [TBL] [Abstract][Full Text] [Related]  

  • 103. The management of stage T1 grade 3 transitional cell carcinoma of the bladder.
    Evans CP; Busby JE
    BJU Int; 2003 Sep; 92(4):345-8. PubMed ID: 12930415
    [No Abstract]   [Full Text] [Related]  

  • 104. Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?
    Goto T; Miyamoto H
    Expert Rev Anticancer Ther; 2020 Apr; 20(4):229-231. PubMed ID: 32208041
    [No Abstract]   [Full Text] [Related]  

  • 105. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
    Schmid SC; Koll FJ; Beckert F; Seitz AK
    Urologe A; 2020 Jul; 59(7):790-796. PubMed ID: 32472221
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.
    Mitin T; Shipley WU; Efstathiou JA; Heney NM; Kaufman DS; Lee RJ; Zietman AL
    Curr Urol Rep; 2013 Apr; 14(2):109-15. PubMed ID: 23341373
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives.
    Kim IH; Lee HJ
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281253
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Urothelial carcinoma in the era of immune checkpoint inhibitors.
    Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
    Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?
    Li R; Spiess PE; Kamat AM
    Eur Urol; 2018 Oct; 74(4):405-408. PubMed ID: 29685644
    [TBL] [Abstract][Full Text] [Related]  

  • 110. [Prediction of local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. A novel risk stratification].
    Weiss C
    Strahlenther Onkol; 2013 Nov; 189(11):984-5. PubMed ID: 24104873
    [No Abstract]   [Full Text] [Related]  

  • 111. Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics.
    Ślusarczyk A; Zapała P; Zapała Ł; Piecha T; Radziszewski P
    Int Urol Nephrol; 2019 Jul; 51(7):1089-1099. PubMed ID: 31154583
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Recent clinical trials in superficial bladder cancer.
    Oosterlinck W
    Curr Opin Urol; 2001 Sep; 11(5):511-5. PubMed ID: 11493773
    [TBL] [Abstract][Full Text] [Related]  

  • 113. The integration of chemotherapy and surgery for bladder cancer.
    Galsky MD; Herr HW; Bajorin DE
    J Natl Compr Canc Netw; 2005 Jan; 3(1):45-51. PubMed ID: 19813322
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Bladder cancer, 1996.
    Lamm DL; Torti FM
    CA Cancer J Clin; 1996; 46(2):93-112. PubMed ID: 8624800
    [TBL] [Abstract][Full Text] [Related]  

  • 115. The landscape of immunotherapy in metastatic urothelial carcinoma.
    Teo MY; Iyer G
    Curr Opin Urol; 2019 Nov; 29(6):643-648. PubMed ID: 31567441
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Updates on intravesical therapy.
    Pisano F; Vila Reyes H; Breda A; Palou J
    Curr Opin Urol; 2019 Nov; 29(6):649-655. PubMed ID: 31567439
    [TBL] [Abstract][Full Text] [Related]  

  • 117. [Follow-up of bladder cancer : The right examinations at the right time].
    Olbert P; Goebell PJ; Hegele A
    Urologe A; 2018 Jun; 57(6):693-701. PubMed ID: 29663062
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?
    Pardo JC; Ruiz de Porras V; Plaja A; Carrato C; Etxaniz O; Buisan O; Font A
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872531
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.
    Vashistha V; Quinn DI; Dorff TB; Daneshmand S
    BMC Cancer; 2014 Dec; 14():966. PubMed ID: 25515347
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Bladder cancer.
    Ozen H
    Curr Opin Oncol; 1992 Jun; 4(3):435-41. PubMed ID: 1498153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.